William Irvin

2.0k total citations
44 papers, 973 citations indexed

About

William Irvin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, William Irvin has authored 44 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Genetics. Recurrent topics in William Irvin's work include Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (10 papers) and Pharmacogenetics and Drug Metabolism (9 papers). William Irvin is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (10 papers) and Pharmacogenetics and Drug Metabolism (9 papers). William Irvin collaborates with scholars based in United States, Canada and India. William Irvin's co-authors include Lisa A. Carey, Hyman B. Muss, Deborah K. Mayer, Howard L. McLeod, Daniel L. Hertz, Laurel W. Rice, Willie A. Andersen, Charles M. Perou, Eric P. Winer and LA Carey and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

William Irvin

41 papers receiving 946 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Irvin United States	14	511	322	220	198	99	44	973
Wen‐Ying Lee Taiwan	22	323 0.6×	334 1.0×	600 2.7×	156 0.8×	61 0.6×	56	1.3k
Shanthini Mary Crusz United Kingdom	7	504 1.0×	224 0.7×	331 1.5×	161 0.8×	37 0.4×	16	1.1k
Mauricio P. Pinto Chile	20	438 0.9×	298 0.9×	462 2.1×	140 0.7×	160 1.6×	56	1.4k
Susan A. Higgins United States	22	863 1.7×	860 2.7×	336 1.5×	362 1.8×	152 1.5×	58	2.1k
Haoran Li China	14	336 0.7×	345 1.1×	491 2.2×	187 0.9×	27 0.3×	81	1.1k
Ling Huang China	16	429 0.8×	450 1.4×	526 2.4×	285 1.4×	24 0.2×	70	1.3k
Xiaoying Sun China	20	787 1.5×	368 1.1×	663 3.0×	259 1.3×	106 1.1×	50	1.6k
Robert J. Cersosimo United States	16	744 1.5×	189 0.6×	319 1.4×	283 1.4×	170 1.7×	43	1.4k
Zhenhua Li China	15	417 0.8×	139 0.4×	330 1.5×	101 0.5×	114 1.2×	34	1.1k
Elisa Agostinetto Italy	20	1.0k 2.0×	495 1.5×	255 1.2×	439 2.2×	99 1.0×	85	1.5k

Countries citing papers authored by William Irvin

Since Specialization

Citations

This map shows the geographic impact of William Irvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Irvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Irvin more than expected).

Fields of papers citing papers by William Irvin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Irvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Irvin. The network helps show where William Irvin may publish in the future.

Co-authorship network of co-authors of William Irvin

This figure shows the co-authorship network connecting the top 25 collaborators of William Irvin. A scholar is included among the top collaborators of William Irvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Irvin. William Irvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Safgren, Stephanie L., Vera J. Suman, Roberto A. Leon Ferre, et al.. (2025). The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen. Breast Cancer Research and Treatment. 211(1). 261–270.

Toland, Amanda Ewart, Carolyn J. Presley, Heather L. Hampel, et al.. (2024). A video intervention to improve patient understanding of tumor genomic testing in patients with cancer. Cancer Medicine. 13(17). e70095–e70095.

Sanoff, Hanna K., Allison M. Deal, Jai N. Patel, et al.. (2024). A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer. The Oncologist. 29(9). 786–793. 1 indexed citations

Chen, Wendy Y., Karla V. Ballman, Ann H. Partridge, et al.. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 331(20). 1714–1714. 15 indexed citations

Salgado, Teresa M., Emily Mackler, William Irvin, et al.. (2024). Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices. Supportive Care in Cancer. 32(8). 563–563. 1 indexed citations

Salgado, Teresa M., Emily Mackler, William Irvin, et al.. (2023). Oncologists’ responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study. Supportive Care in Cancer. 31(8). 450–450. 1 indexed citations

Trivedi, Meghna S., Joseph M. Unger, Dawn L. Hershman, et al.. (2023). Abstract PD8-06: Incidence of Acute and Persistent Clinically Meaningful Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481). Cancer Research. 83(5_Supplement). PD8–6. 1 indexed citations

Bennison, Craig, et al.. (2022). POSB96 Economic Model for a Gene Therapy in an Ultra-Rare Disease: Expert Validation of Approach and Assumptions. Value in Health. 25(1). S79–S79. 1 indexed citations

Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations

10.

O’Sullivan, Ciara C., Karla V. Ballman, Linda McCall, et al.. (2021). Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer. Future Oncology. 17(34). 4665–4676. 19 indexed citations

11.

Deal, Allison M., Christine M. Walko, Joseph G. Ibrahim, et al.. (2017). Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and Genomics. 27(11). 402–409. 13 indexed citations

12.

Paoletti, Costanza, Yufeng Li, Maria C. Muñiz, et al.. (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research. 21(12). 2771–2779. 75 indexed citations

13.

Vaklavas, Christos, Vandana G. Abramson, Nancy U. Lin, et al.. (2013). TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 31(15_suppl). 1052–1052. 1 indexed citations

14.

Misher, Anne, et al.. (2012). Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. Clinical Chemistry and Laboratory Medicine (CCLM). 50(8). 1329–34. 8 indexed citations

15.

Lin, NU, H. S. Rugo, Rita Nanda, et al.. (2011). TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS128–TPS128. 2 indexed citations

16.

Irvin, William, Robert Z. Orlowski, Lisa A. Carey, et al.. (2010). Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer. Clinical Breast Cancer. 10(6). 465–470. 25 indexed citations

17.

Carey, LA, Hope S. Rugo, P. Kelly Marcom, et al.. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1009–1009. 133 indexed citations

18.

Irvin, William & Lisa A. Carey. (2008). What is triple-negative breast cancer?. European Journal of Cancer. 44(18). 2799–2805. 270 indexed citations

19.

Taylor, Ann Gill, Daniel I. Galper, Peyton T. Taylor, et al.. (2003). Effects of Adjunctive Swedish Massage and Vibration Therapy on Short-Term Postoperative Outcomes: A Randomized, Controlled Trial. The Journal of Alternative and Complementary Medicine. 9(1). 77–89. 41 indexed citations

20.

Irvin, William. (1998). Abdominal tuberculosis mimicking metastatic ovarian carcinoma. Obstetrics and Gynecology. 92(4). 709–709. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact